代谢组学在妇科常见肿瘤治疗和预后评估中的应用

卵巢癌、子宫内膜癌和宫颈癌是妇科常见的三大恶性肿瘤,尽管随着手术、放化疗等综合治疗的不断发展,妇科常见恶性肿瘤患者的预后得到了大幅提升,但由于早期没有明显症状且缺乏准确诊断或发现时已是晚期,仍有相当比例的患者预后不佳,生命受到严重威胁。因此,寻找新的治疗靶点和监测疗效的有效标志物至关重要。代谢组学（metabonomics）是肿瘤研究领域颇受关注的研究方法,其理论基础是肿瘤存在有别于正常组织的代谢特征,肿瘤独特的代谢特征与生物表型存在紧密的关联。代谢组学通过对生物系统中内源性代谢物进行全面分析,阐明肿瘤在发生和进展过程中某些关键生化途径的重塑机制,并对其进行解析与精准干预。综述代谢组学在妇科常见肿瘤治疗和预后评估中的应用,预期其可为妇科常见肿瘤的个性化、精准化治疗提供潜在靶点,为妇科常见肿瘤筛选预后生物标志物提供重要参考。

Application of Metabonomics in the Treatment and Prognosis of Common Gynecological Tumors

Ovarian cancer, endometrial cancer and cervical cancer are three major malignancies in gynecology. The prognosis of patients with gynecologic tumors has been improved significantly with the development of comprehensive treatments such as surgery, radiotherapy and chemotherapy, however, due to the lack of obvious symptoms and accurate diagnosis at early stages, there are still a considerable proportion of patients with poor prognosis life-threatening. Therefore, it is very important to identify new therapeutic targets and predictive markers for prognosis. Metabolomics is a popular research method in the field of cancer research. Its theoretical basis is that tumors have different metabolic characteristics from normal tissues, which are closely related to biological phenotypes. Through comprehensive analysis of endogenous metabolites in biological systems, metabolomics elucidates the remodeling mechanism of some key biochemical pathways during tumor development and progression, and provides analytical and precise intervention. This paper reviews the application of metabonomics in the treatment and prognosis of gynecological tumors, which is expected to provide potential targets for personalized and precise treatment of gynecological tumors, and provide important reference for selecting biomarkers for prognosis of gynecological tumors.